家族性腺瘤性息肉病患者癌症风险:丹麦全国队列研究与匹配对照
基于丹麦全国息肉病登记库的匹配队列研究纳入565例家族性腺瘤性息肉病(FAP)患者与1890例对照,FAP患者总体癌症风险显著升高(HR 4.12),主要源于结直肠癌、胰腺癌及十二指肠/小肠癌,第二原发癌风险亦升高(HR 1.89),1980至2020年间FAP患者癌症风险下降约50%。
要点
- FAP患者总体癌症风险显著高于匹配对照(HR 4.12,95%CI 3.28-5.17)。
- 结直肠癌、胰腺癌及十二指肠/小肠癌风险显著升高,胃癌无显著差异。
- FAP患者第二原发癌风险显著升高(HR 1.89,95%CI 1.02-3.50)。
核心结论
- 尽管FAP患者癌症风险绝对下降,其风险仍显著高于背景人群,主要归因于结直肠癌、胰腺癌及十二指肠/小肠癌。
研究设计与样本
- 基于丹麦全国息肉病登记库的匹配队列研究,纳入截至2021年4月所有已知FAP患者,按出生年份、性别和邮政编码1:4匹配对照。
- 分析共纳入565例FAP患者和1890例对照。
主要发现
- FAP患者总体癌症风险显著高于对照(HR 4.12,95%CI 3.28-5.17,P < .001)。
- 结直肠癌风险显著升高(HR 4.61,95%CI 2.58-8.22,P < .001)。
- 胰腺癌风险显著升高(HR 6.45,95%CI 2.02-20.64,P = .002)。
- 十二指肠/小肠癌风险显著升高(HR 14.49,95%CI 1.76-119.47,P = .013)。
- 胃癌风险无显著差异(HR 3.29,95%CI 0.53-20.23,P = .20);第二原发癌风险显著升高(HR 1.89,95%CI 1.02-3.50,P = .042)。
关键数值与推荐
- FAP患者总体癌症风险HR 4.12(95%CI 3.28-5.17,P < .001)。
- 结直肠癌HR 4.61(95%CI 2.58-8.22,P < .001)。
- 胰腺癌HR 6.45(95%CI 2.02-20.64,P = .002)。
- 十二指肠/小肠癌HR 14.49(95%CI 1.76-119.47,P = .013)。
- 第二原发癌HR 1.89(95%CI 1.02-3.50,P = .042);1980至2020年间FAP患者癌症风险下降约50%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Familial adenomatous polyposis (FAP) is a hereditary disorder that predisposes patients to colorectal cancer (CRC). Prophylactic colectomy has greatly reduced the risk of CRC. However, new associations between FAP and the risk of other cancers have subsequently emerged. In this study, we assessed the risk of specific primary and secondary cancers among patients with FAP compared with matched controls. METHODS: All known patients with FAP up until April 2021 were identified in the nationwide Danish Polyposis Register and paired with 4 unique controls matched by birth year, sex, and postal code. The risk of overall cancers, specific cancer types, and risk of a second primary cancer was assessed and compared with controls. RESULTS: The analysis included 565 patients with FAP and 1890 controls. The overall risk of cancer was significantly higher for patients with FAP than for controls (hazard ratio [HR], 4.12; 95% confidence interval [CI], 3.28-5.17; P < .001). The increased risk was mainly due to CRC (HR, 4.61; 95% CI, 2.58-8.22; P < .001), pancreatic cancer (HR, 6.45; 95% CI, 2.02-20.64; P = .002), and duodenal/small-bowel cancer (HR, 14.49; 95% CI, 1.76-119.47; P = .013), whereas no significant difference was observed for gastric cancer (HR, 3.29; 95% CI, 0.53-20.23; P = .20). Furthermore, the risk of a second primary cancer was significantly higher for patients with FAP (HR, 1.89; 95% CI, 1.02-3.50; P = .042). Between 1980 and 2020, the risk of cancer among patients with FAP decreased by ∼50%. CONCLUSIONS: Despite an absolute reduction in the risk of developing cancer among patients with FAP, the risk remained significantly higher than for the background population due to colorectal, pancreatic, and duodenal/small-bowel cancers.
引用
- Karstensen JG, Bülow S, Højen H, et al. Cancer in Patients With Familial Adenomatous Polyposis: A Nationwide Danish Cohort Study With Matched Controls. Gastroenterology. 2023. PMID: 37201686. doi:10.1053/j.gastro.2023.05.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。